$12.30
-0.31(-2.46%)
Mkt Cap $14M
$3.13
$1710.00
52-Week Range
At a Glance
AI-generatedPolyrizon Ltd., a clinical-stage biotech company developing nasal hydrogel technologies, reported a net loss of $3.3 million for FY 2025, up 116% from $1.5 million in FY 2024, driven by ramped-up R&D post-IPO.
$14M
Market Cap
—
Revenue
-$691.3K
Net Income
Employees2
Fundamentals
How The Business Makes Money
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001893645
ISINIL0011814113
CUSIPM79549123
Phone972 9 374 0120
Address5 Ha-Tidhar Street, Ra'anana, 4366507, IL
SEC EDGAR